Bank of America
LRMR icon

Bank of America’s Larimar Therapeutics LRMR Stock Holding History

Bank of America’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$213K Buy
47,359
+6,886
+17% +$27.5K ﹤0.01% 5331
2025
Q4 		$154K Buy
40,473
+12,326
+44% +$47.9K ﹤0.01% 5457
2025
Q3 		$90.9K Sell
28,147
-20,430
-42% -$76.6K ﹤0.01% 6638
2025
Q2 		$140K Sell
48,577
-1,799
-4% -$4.17K ﹤0.01% 6349
2025
Q1 		$108K Sell
50,376
-2,814
-5% -$8.89K ﹤0.01% 6454
2024
Q4 		$206K Buy
53,190
+3,980
+8% +$26.3K ﹤0.01% 6110
2024
Q3 		$322K Buy
49,210
+2,629
+6% +$21.1K ﹤0.01% 5753
2024
Q2 		$338K Buy
46,581
+6,858
+17% +$52.5K ﹤0.01% 5583
2024
Q1 		$301K Buy
39,723
+14,845
+60% +$116K ﹤0.01% 5654
2023
Q4 		$113K Buy
24,878
+7,687
+45% +$25.9K ﹤0.01% 6330
2023
Q3 		$67.9K Sell
17,191
-46,911
-73% -$177K ﹤0.01% 6398
2023
Q2 		$201K Buy
64,102
+41,231
+180% +$168K ﹤0.01% 5827
2023
Q1 		$104K Buy
22,871
+22,807
+35,636% +$119K ﹤0.01% 6244
2022
Q4 		$264 Buy
64
+61
+2,033% +$208 ﹤0.01% 7502
2022
Q3 		$0 Sell
3
-210
-99% -$526 ﹤0.01% 8039
2022
Q2 		$0 Sell
213
-116,010
-100% -$343K ﹤0.01% 8220
2022
Q1 		$471K Buy
116,223
+43,713
+60% +$286K ﹤0.01% 5881
2021
Q4 		$782K Sell
72,510
-9,300
-11% -$103K ﹤0.01% 5499
2021
Q3 		$944K Buy
81,810
+75,176
+1,133% +$902K ﹤0.01% 5140
2021
Q2 		$65K Sell
6,634
-53,066
-89% -$600K ﹤0.01% 6712
2021
Q1 		$872K Buy
59,700
+56,272
+1,642% +$1.02M ﹤0.01% 4951
2020
Q4 		$73K Sell
3,428
-45,619
-93% -$914K ﹤0.01% 6144
2020
Q3 		$744K Buy
49,047
+46,421
+1,768% +$588K ﹤0.01% 4430
2020
Q2 		$34K Buy
2,626
+1,710
+187% +$19.9K ﹤0.01% 6126
2020
Q1 		$8K Sell
916
-485
-35% -$6.38K ﹤0.01% 6416
2019
Q4 		$19K Sell
1,401
-421
-23% -$4.02K ﹤0.01% 6515
2019
Q3 		$16K Sell
1,822
-1,338
-42% -$14.7K ﹤0.01% 6631
2019
Q2 		$45K Sell
3,160
-4,936
-61% -$131K ﹤0.01% 6341
2019
Q1 		$266K Buy
8,096
+6,437
+388% +$330K ﹤0.01% 5384
2018
Q4 		$98K Buy
1,659
+1,010
+156% +$99.7K ﹤0.01% 5929
2018
Q3 		$91K Sell
649
-290
-31% -$35.2K ﹤0.01% 5918
2018
Q2 		$115K Sell
939
-121
-11% -$10.3K ﹤0.01% 5726
2018
Q1 		$95K Buy
1,060
+484
+84% +$41K ﹤0.01% 5760
2017
Q4 		$32K Buy
576
+8
+1% +$361 ﹤0.01% 6254
2017
Q3 		$24K Sell
568
-653
-53% -$27.2K ﹤0.01% 6206
2017
Q2 		$51K Buy
1,221
+312
+34% +$16K ﹤0.01% 5865
2017
Q1 		$51K Sell
909
-58
-6% -$2.88K ﹤0.01% 5921
2016
Q4 		$37K Buy
967
+317
+49% +$12.9K ﹤0.01% 6067
2016
Q3 		$26K Sell
650
-202
-24% -$9.17K ﹤0.01% 6016
2016
Q2 		$61K Buy
852
+284
+50% +$22.4K ﹤0.01% 5750
2016
Q1 		$46K Sell
568
-616
-52% -$48.6K ﹤0.01% 5820
2015
Q4 		$89K Sell
1,184
-1,955
-62% -$314K ﹤0.01% 5784
2015
Q3 		$1.2M Buy
3,139
+665
+27% +$300K ﹤0.01% 4189
2015
Q2 		$1.03M Buy
2,474
+2,472
+123,600% +$1.03M ﹤0.01% 4086
2015
Q1 		$1K Sell
2
-15
-88% -$7.12K ﹤0.01% 6818
2014
Q4 		$6K Buy
+17
New +$4.38K ﹤0.01% 7221

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Bank of America's LRMR Position: Q1 2026 in Review

Bank of America increased its Larimar Therapeutics (LRMR) stake by 17% in Q1 2026, buying an estimated $27.5K and bringing the position to 47,359 shares worth $213K. The position accounts for ﹤0.01% of the portfolio, ranked #5331.

Bank of America first reported a position in LRMR in Q4 2014 and has held it in 46 quarters since. The position peaked at $1.2M in Q3 2015. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Bank of America held 47,359 shares of Larimar Therapeutics worth $213K as of Q1 2026.
  • Bank of America bought 6,886 Larimar Therapeutics shares in Q1 2026, an estimated $27.5K.
  • Larimar Therapeutics made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #5331 holding.
  • Bank of America first reported a position in Larimar Therapeutics in Q4 2014 and has held it in 46 quarters since.
  • Bank of America's Larimar Therapeutics position peaked at $1.2M in Q3 2015.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.